Tech Company Financing Transactions
GluBio Therapeutics Funding Round
On 8/1/2022, GluBio Therapeutics raised $22 million in Series A funding from Qiming Ventures, Kaitai Capital and Lilly Asia Ventures.
Transaction Overview
Company Name
Announced On
8/1/2022
Transaction Type
Venture Equity
Amount
$22,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to advance two molecular glue degraders into the clinic for hematological malignancies, accelerate the lead optimization entry of three first-in-class TPD drugs for solid tumors and inflammatory diseases, and further upgrade its proprietary TPD discovery platform and screening capabilities tailored for rapid discovery and optimization of small molecule protein degraders for 'undruggable' therapeutic targets.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
Room 810 8th Floor Hemao Building No. 1116 Xingsha South Xin
Hangzhou Zhejiang, Undisclosed
China
Hangzhou Zhejiang, Undisclosed
China
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
GluBio Therapeutics focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gang Lu
Browse more venture capital transactions:
Prev: 8/1/2022: Tuotuo Digital venture capital transaction
Next: 8/1/2022: Concert Bio venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here come from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs